首页 | 本学科首页   官方微博 | 高级检索  
     

肿瘤标志物在肺癌联合诊断的临床应用分析
引用本文:吴志德. 肿瘤标志物在肺癌联合诊断的临床应用分析[J]. 安徽医药, 2013, 17(5): 793-795
作者姓名:吴志德
作者单位:湖北省武穴市第一人民医院检验科,湖北,武穴,435400
摘    要:目的研究肺癌病理类型与肿瘤标志物关系及多肿瘤标志物联合检测对肺癌诊断的临床应用价值。方法回顾性分析该院68例肺癌患者临床资料,研究肺癌病理类型与肿瘤标志物关系,利用方法学指标评价多肿瘤标志物联合检测对肺癌诊断的临床应用价值。结果肺癌组CEA、CA125、NSE血清水平与异常率与肺良性病变组及对照组比较均有统计学差异(P0.05),CEA、CA125对腺癌有一定特异性,其血清浓度分别为(68.5±21.5)μg·L-1、(98.5±31.2)U.mL-1与鳞癌、小细胞癌比较有统计学差异(P0.05),NSE血清浓度小细胞癌较高为(45.5±7.7)μg·L-1与鳞癌、腺癌比较有统计学差异(P0.05);肺癌组中Ⅰ~Ⅱ期患者CEA、CA125、NSE血清浓度均低于Ⅲ~Ⅳ期患者,两组比较有统计学差异(P0.05);三种肿瘤标志物灵敏度以CEA 51.5%、特异度以CA125 93.2%较好,联合检测可大幅提高检测的灵敏度(73.5%)及约登指数(0.57)。结论 CEA、CA125、NSE对肺癌诊断、疗效观察及肺癌复发的监测均有重要的临床应用价值,三种肿瘤标志物的联合检测可提高肺癌诊断的准确率。

关 键 词:肿瘤标志物  肺癌  鳞癌  腺癌  小细胞癌  癌胚抗原  糖类抗原125  神经元烯醇化酶

Clinical application of combined detection of tumor markers to thediagnosis of lung cancer
WU Zhi-de. Clinical application of combined detection of tumor markers to thediagnosis of lung cancer[J]. Anhui Medical and Pharmaceutical Journal, 2013, 17(5): 793-795
Authors:WU Zhi-de
Affiliation:WU Zhi-de (Department of Laboratory Tests, The First People' s Hospital, Wuxue ,Hubei 435400, China)
Abstract:Objective To study the pathological type of lung cancer and tumor markers relations and multiumor markers combined detection of clinical value in the diagnosis of lung cancer. Methods A retrospective analysis was made of the clinical data of 68 cases of lung cancer patients in our hospital to study the relationship between the pathological type of lung cancer and tumor markers. We used the methodology to evaluate combined detection of tumor markers in the diagnosis of lung cancer clinical value. Results CEA, CA125, NSE, NSE serum levels and abnormal rate of lung cancer group, benign lung group and control group were significantly different ( P 〈 0.05 ). CEA, CA125 had to certain specificity adenocarcinoma. Serum concentrations were ( 68.5 ± 21.5 )μg. L- 1, ( 98.5 ± 31.2 ) μmL- compared with squamous cell carcinoma, small cell carcinoma with significant difference ( P 〈 0.05 ). NSE serum concentrations was higher for small cell carcinoma (45.5 ± 7.7)μg . L-1 compared with squamous cell carcinoma, adenocarcinoma, with a significant difference (P 〈 0.05) ; as for lung cancer group I - Ⅱ patients CEA, CA125 and NSE serum concentrations were lower than those of IU-IV stage patients. The two groups had a significant difference(P 〈 0.05). As for sensitivity of three tumor markers CEA was 51.5%, specificity of CA125 93.2%. Joint detection can significantly improve the detection sensitivity(73.5% ) and Youden index(0.57). Conclu- sion CEA, CA125,NSE have clinical significance for the diagnosis of lung cancer, curative effect observation and lung cancer recurrence monitoring. Combined test of three kinds of tumor markers in diagnosis of lung cancer can improve the accuracy rate.
Keywords:tumor marker  lung cancer  squamous cell carcinoma  adenocarcinoma  small cell cancer  carcinoembryonic antigen  carbohy-drate antigen 125  NSE
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号